PTGX
Protagonist Therapeutics, Inc.
$154.32
+2.41%
2026-08-21
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Key Fundamentals
P/E Ratio
152.06
Forward P/E
-1109.28
EPS (TTM)
$1.02
ROE
11.0%
Revenue Growth (YoY)
3749.2%
Profit Margin
29.4%
Debt/Equity
1.09
Price/Book
11.92
Beta
1.79
Market Cap
$10.04B
Avg Volume (10D)
482K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$160.81
60D Low
$92.75
Avg Volume
686K
Latest Close
$154.32
Get breakout alerts for PTGX
Sign up for Breakout Scanner to receive daily notifications when PTGX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Protagonist Therapeutics, Inc. (PTGX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors PTGX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. PTGX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.